安道药业

Kind strives to form a new drug development pattern focusing on small molecule targeted drugs and biomacromolecule drugs to treat anemia, cancers, and hard-to-treat diseases.

At Kind, we have aimed to build a vibrant international biopharmaceutical company with diversified innovative capabilities, and we are dedicated to contributing to human health.

We are keen to bring novel, effective, and affordable therapies to global patients to meet unmet medical needs.

Our mission is to be Good to Human, Humble to Science, and Kind to Patients.